论文部分内容阅读
目的 :检测乳腺癌P5 3、C -erbB - 2、组织蛋白酶D和C -myc癌基因蛋白在乳腺癌的表达并了解它们与乳腺癌生物学行为的关系。方法 :对乳腺癌 76例和乳腺良性病变 2 1例进行P5 3、C -erbB - 2、组织蛋白酶D和C -myc蛋白免疫组化检测。结果 :a .P5 3和C -erbB - 2仅在乳腺癌有表达。组织蛋白酶D在乳腺良恶性病变表达率存在显著差异 (P <0 0 1)。P5 3和组织蛋白酶D表达率随乳腺癌组织学分级升高而上升 (P <0 0 5 )。b .浸润性导管癌和乳头乳晕湿疹样癌C -erbB - 2阳性表达明显高于其它类型 (P <0 0 1)。c .C -myc癌基因蛋白在乳腺良恶性病变表达率无明显差异。结论 :P5 3、C -erbB - 2和组织蛋白酶D可作为乳腺癌诊断的依据 ,P5 3和组织蛋白酶D对乳腺癌预后的评估 ,C -erbB - 2对乳腺癌组织学类型的鉴别有重要意义
OBJECTIVE: To detect the expression of P53, C-erbB-2, cathepsin D and C-myc oncoproteins in breast cancer and to investigate their relationship with the biological behavior of breast cancer. Methods: P53, C-erbB-2, cathepsin D and C -myc protein were detected by immunohistochemistry in 76 cases of breast cancer and 21 cases of benign breast lesions. Results: a. P5 3 and C-erbB - 2 were only expressed in breast cancer. The expression of cathepsin D in benign and malignant breast lesions was significantly different (P <0.01). P5 3 and cathepsin D expression increased with the histological grade of breast cancer (P <0.05). b. The positive expression of C-erbB-2 in invasive ductal and nipple-areola eczematous carcinomas was significantly higher than that in other types (P <0.01). c. C -myc oncogene protein expression in benign and malignant breast lesions no significant difference. Conclusion: P5 3, C - erbB - 2 and cathepsin D can be used as the basis for the diagnosis of breast cancer. P5 3 and cathepsin D can be used to evaluate the prognosis of breast cancer. C - erbB - 2 is important in the differential diagnosis of breast cancer significance